Infection,
Veterinary medicine,
Silver,
Medicine,
Noetics,
Hygiene,
LOI,
ISIN,
Growth,
Health,
FDA,
Trauma,
Medical device Nuremberg/Bremen, July 31, 2023 - Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has concluded a preliminary agreement (LOI, Letter-of-Intent) with a North American medical device manufacturer focusing on the trauma sector.
Key Points:
- Nuremberg/Bremen, July 31, 2023 - Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has concluded a preliminary agreement (LOI, Letter-of-Intent) with a North American medical device manufacturer focusing on the trauma sector.
- The medical device manufacturer intends to use Bio-Gate's "HyProtectTM" coating process for its own implants in human medicine following the FDA approval process.
- With the North American medical device manufacturer, Bio-Gate has gained another important company as a partner for its "HyProtect" coating technology and can develop significant growth potential in applications for human medicine in the future.
- Bio-Gate uses the "HyProtect" technology to coat medical devices with an ultra-thin layer containing polysiloxane and silver.
Retrieved on:
Thursday, February 2, 2023